GlassScriptPhysician profile
William D Yarbrough
NPI 1225083702
$18,894.50
in general payments reported to CMS, 2019-2025
41 companies · $1,991 in 2025
The $1,991 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,950 · 2020: $814 · 2021: $1,253 · 2022: $1,412 · 2023: $2,351 · 2024: $1,123 · 2025: $1,991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,232 · Travel and Lodging: $1,232 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,231.66 |
| Travel and Lodging | $1,232.32 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $8,690.79 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $1,679.48 | 2021-2025 | Verquvo, Winrevair |
| Abbott Laboratories | $1,113.65 | 2019-2025 | Aveir, Jot Dx, Cardiomems |
| E.R. Squibb & Sons, L.L.C. | $1,065.48 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $751.76 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $720.12 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $534.26 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $472.08 | 2019-2025 | Farxiga |
| Boston Scientific Corporation | $445.91 | 2019-2025 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $429.32 | 2019-2025 | Lifevest |
| Heartflow, INC. | $384.41 | 2019-2025 | |
| Pfizer INC. | $292.79 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $242.44 | 2021-2025 | Onpattro, Amvuttra |
| Philips North America LLC | $239.89 | 2024-2025 | (Cm9) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided, (K95) Ecc Solutions |
| Medtronic, INC. | $218.66 | 2021-2025 | Azure Xt Dr Mri Surescan, Aurora Ev-Icd Mri Surescan, Linq II |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $194.96 | 2024-2025 | Wegovy |
| Edwards Lifesciences Corporation | $186.67 | 2022-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Esperion Therapeutics, INC. | $148.82 | 2021-2025 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $146.26 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $145.55 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.32 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $81.24 | 2019 | |
| Atricure, INC. | $75.84 | 2022-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Kiniksa Pharmaceuticals, LTD. | $66.69 | 2023 | Arcalyst |
| Bridgebio Pharma, INC. | $61.86 | 2025 | Attruby |
| Arbor Pharmaceuticals, INC. | $52.84 | 2019-2020 | |
| Biotronik INC. | $52.28 | 2021-2024 | Biomonitor, Amvia Edge |
| Cardiva Medical, INC. | $39.62 | 2022 | |
| Cvrx, INC. | $35.95 | 2023-2024 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $35.57 | 2019-2023 | Opsumit, Uptravi |
| Lexicon Pharmaceuticals, INC. | $30.68 | 2023 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $29.10 | 2019 | |
| Angiodynamics, INC. | $27.57 | 2025 | Alphavac |
| Kowa Pharmaceuticals America, INC. | $26.43 | 2019-2020 | |
| Astellas Pharma US INC | $22.84 | 2021 | |
| Hitachi Healthcare Americas Corp. | $22.12 | 2019 | |
| G Medical Diagnostic Services, INC. | $16.65 | 2022 | |
| Glaxosmithkline, LLC. | $15.60 | 2025 | Shingrix, Arexvy |
| Bardy Diagnostics, INC. | $12.00 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Yarbrough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.